ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the sale, the chief financial officer owned 166,143 shares of the company’s stock, valued at approximately $12,106,840.41. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.6%

NASDAQ ANIP opened at $72.00 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 52 week low of $69.58 and a 52 week high of $95.57. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 2.36 and a beta of 0.50. The company has a fifty day moving average of $72.96 and a two-hundred day moving average of $77.68.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership grew its position in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after acquiring an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. purchased a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $28,406,000. Deutsche Bank AG purchased a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $26,775,000. Finally, William Blair Investment Management LLC purchased a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $21,372,000. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ANIP shares. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $99.60.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.